Halozyme Therapeutics Inc (HALO)

[maumar]

"South Korea’s Celltrion has managed to get its near-copy of MabThera – to be called Truxima – through the rigorous regulatory process for biosimilars, showing that it is as safe and effective as the originator.

But it remains to be seen how much market share the biosimilar will get, as Roche has shrewdly protected MabThera with a more convenient subcutaneous formulation that cuts the infusion time from several hours to a few minutes.

Celltrion’s biosimilar does not have this advantage, and will instead have to rely on price alone to win over prescribers and patients."

https://pharmaphorum.com/news/roche-mabthera-faces-cheaper-rival-eu/